ZULEMA ALCARAZ: Open Payments
NPI 1578271417 · CLEBURNE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,584 in 87 payments from 22 companies in 2025. Trend: 2023 $954 · 2024 $733 · 2025 $1,584
Food & beverage: $1,584
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $209 |
| Novo Nordisk Inc | 9 | $178 |
| PFIZER INC. | 13 | $162 |
| AstraZeneca Pharmaceuticals LP | 9 | $155 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $146 |
| SANOFI-AVENTIS U.S. LLC | 4 | $109 |
| SHIELD THERAPEUTICS INC | 3 | $78 |
| Axsome Therapeutics, Inc. | 3 | $71 |
| Lilly USA, LLC | 4 | $62 |
| Exact Sciences Corporation | 3 | $57 |
Products named: CAPLYTA, VRAYLAR, NURTEC ODT, Wegovy, TZIELD, AIRSUPRA, ACCRUFER, QULIPTA.
Industry payments across TX — which companies pay providers there.
